EDEN Eden Research

EQS-News: Eden granted US EPA regulatory approval

EQS-News: Eden Research plc
Eden granted US EPA regulatory approval

27.09.2022 / 18:06 CET/CEST
The issuer is solely responsible for the content of this announcement.


(, the AIM-quoted company focused on sustainable biopesticides and for use in the global crop protection, and , is pleased to announce that it has received regulatory approval from the , for all five petitions submitted, covering the Company’s three active ingredients (eugenol, geraniol and thymol) and two formulated products (and ).

The EPA approval of Eden’s products and active ingredients will open significant revenue opportunities for Eden, with of approximately €94m for and €189m for . In addition, the Board expects that ultimately the registration of Eden’s developmental insecticide will follow a shortened timeline as it is based upon the now-approved active ingredients. Eden will pursue registration of this new product in due course based upon the outcome of field trials. The total market potential for the insecticide is €237m.

Farmers in the US spend hundreds of millions of dollars every year on products that protect crops from diseases and pests that contribute to lost yields, food waste and inefficient production. Pesticides make up a large percentage of the overall spend on crop inputs. However, regulators around the world have banned a growing number of commonly used conventional chemical pesticide products in recent years, and farmers need to keep up with growing demand for food production. As a result, they are increasingly turning to , like Eden’s and , which are based on natural substances and offer a more , without compromising efficacy, safety, yield or production costs.

Coastal and southern states such as California and Florida will be the initial focus for the use of Eden’s products given the prevalence of high value horticultural crops where Eden’s products currently deliver the highest value. Marketing of the products will commence as soon as possible, subject to state level regulatory approval in these regions, which is expected in the coming months. Assuming timely state-level authorizations, meaningful sales are expected to commence in 2023 following the past several years during which preparations have been made for product launches.

, Chief Executive Officer of Eden Research plc, commented:

“Eden has been at the forefront of accelerating change in the input market for several years, and our authorizations in the US mark the next milestone in this journey, significantly expanding our addressable market to include the second largest food market in the world.

As a small but innovative UK business, we are proud of the impact that Eden can have on the global stage. Despite our size, we export our pioneering products and technologies to Europe, Africa, Australia, and North America, partnering with some of the largest global players in the crop protection industry.

The EPA authorizations are the result of over four years of effort by our experienced regulatory, development and commercial teams who worked tirelessly to ensure that Eden addressed the EPA’s extensive and evolving list of strict requirements.

We are among the very few British crop protection companies to receive approvals for multiple in the US, and we believe we are the smallest company to achieve the ambitious goal of registering three active ingredients and two formulated products at once, thereby opening up one of the world’s most important markets for agricultural inputs”.

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz.

Contact Details

Eden Research plc

Alex Abrey

Company Website


News Source: News Direct


27.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Eden Research plc
United States
ISIN: GB0001646941
EQS News ID: 1451503

 
End of News EQS News Service

1451503  27.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1451503&application_name=news&site_id=research_pool
EN
27/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eden Research

Hybridan Small Cap Feast - 07 May 2024

7th May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: Dual Listing: Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email with “unsubscribe me”. Hybridan Chefs Banquet...

Hybridan Small Cap Feast - 22 Jan 24

22nd January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje...

Emily Liu
  • Emily Liu

Hybridan Small Cap Feast 05/10/2023

Dish of the day Joiners: No joiners today. Leavers: Pittards has left AIM. What’s cooking in the IPO kitchen?** Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Admission expected on 10 October. Announced ITF 26 September: Mydecine Innovations Gr...

Sacha Morris
  • Sacha Morris

Hybridan Small Cap Feast 16/08/2023

Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Announced ITF 4 August: Tan Delta Systems plc, a Sheffield based Company intends to IPO on AIM. Tan Delta has developed an innovative and differentiated monitoring solution based on real time oil analysis and analytics that offers equipment operators enhanced insight into the maintenance status of their equipment and thus the ability to reduce maintenance costs, improve reliability and reduce carbon footpr...

Hybridan Small Cap Feast - 03 Jul 23

3rd July 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch